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Abstract: Patients with type 2 diabetes mellitus (T2DM) have an increased risk of cardiovascular 
disease (CVD). Unfortunately, several potential barriers exist for CVD risk management in dia-
betes, including the need for signiﬁ  cant lifestyle changes, potential problems with hypoglycemia, 
weight gain, injection tolerability, treatment complexity with current diabetes therapies and other, 
unmodiﬁ  able factors. Improving glycemic control may impact CVD risk. Treatment of T2DM 
usually starts with lifestyle changes such as diet and exercise. When these become insufﬁ  cient, 
pharmacotherapy is required. Various oral antidiabetic drugs (OADs) are available that reduce 
hyperglycemia. The ﬁ  rst line of therapy is usually metformin, since it does not increase weight 
and seems to have a beneﬁ  cial effect on CVD mortality and risk factors. As T2DM progresses, 
insulin treatment becomes necessary for the majority of patients. The last few years have seen 
the development of long-acting, rapid-acting, and premixed insulin analog formulations. The 
treat-to-target algorithms of recent studies combining OADs plus insulin analogs have dem-
onstrated that patients can reach glycemic treatment targets with low risk of hypoglycemia, 
greater convenience, and – with some analogs – limited weight gain vs conventional insulins. 
These factors may possibly have a positive inﬂ  uence on CVD risk. Future studies will hopefully 
elucidate the beneﬁ  ts of this approach.
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Introduction
Type 2 diabetes mellitus (T2DM), a progressive disease characterized by insulin 
resistance and eventual insulin deﬁ  ciency, is caused by a gradual decrease of insulin 
secretion following loss of beta-cell function (Polonsky 1988). This pathology results in 
progressively increasing blood glucose levels. Typically, postprandial plasma glucose 
(PPG) becomes elevated ﬁ  rst, with fasting glucose ultimately increasing as well (Coates 
1994). Interventional studies have established chronic high blood glucose (assessed by 
HbA1c) as a CVD risk factor (Stratton et al 2000; Davis et al 2001). That elevated PPG 
is an independent risk factor for CVD has further been implicated from epidemiologi-
cal studies (DECODE 2001). Diabetes is also associated with other risk factors such 
as hypertension, adverse lipid proﬁ  les and obesity. Even after correcting for these risk 
factors, CVD rates are still higher in patients with diabetes than in non-diabetic subjects, 
implying that hyperglycemia per se may amplify the underlying risk of CVD.
This increased risk of CVD and related problems leads to a higher risk of mortal-
ity compared with the general population. Epidemiological research conducted by the 
Centers for Disease Control and Prevention (CDC) (CDC 2003) examined the impact of 
T2DM on cardiovascular events and mortality, reaching the following conclusions:
•  CVD is the leading cause of death among patients with diabetes;Vascular Health and Risk Management 2008:4(3) 562
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Figure 1 Improvement in glycemic control reduces risks of long-term complications 
(Stratton et al 2000).
•  CVD death rates are 2–4 times higher in adults with 
diabetes than in controls;
•  Risk for stroke is 2–4 times higher among patients with 
diabetes than in those without it.
The objective of this article is to provide an overview of 
CVD risk factors in diabetes with emphasis on the role of 
glycemic control, and to examine whether current therapies 
in T2DM have beneﬁ  cial effects on markers of macrovas-
cular disease. Using recent data from treat-to-target trials, 
the review will consider insulin plus oral antidiabetic drug 
(OAD) treatments and their effect on glycemic control and 
cardiovascular risk factors.
Cardiovascular (CV) risk in diabetes
Although mortality due to CVD is declining in non-dia-
betic populations, patients with T2DM are at a high risk 
of CV morbidity and mortality (Kannel and McGee 1979; 
Schernthaner 1996). Some studies have reported that 
almost 75% of patients with T2DM die of macrovascular 
events, such as acute myocardial infarction (MI) and 
stroke (Laakso 1995). In a mortality study of more than 
3000 patients, 4-year survival was 92% for patients with 
diabetes duration  5 years, and 84% if diabetes duration 
was  5 years (Bo et al 2006). Most deaths were due to 
CVD (36% and 41% for diabetes duration  5 years and 
 5 years, respectively) (Bo et al 2006). A 7-year Finnish 
study suggested that the CV event rate for patients with 
diabetes without prior MI was as high as the event rate 
in patients without diabetes with prior MI (Haffner et al 
1998).
CVDs common in T2DM include coronary artery 
disease, stroke, peripheral vascular disease, cardiomyopa-
thy and congestive heart failure. Several of these patholo-
gies are usually present in a majority of patients; therefore 
most patients require multiple interventions (Kannel 2000). 
At the 2007 annual meeting of the American Diabetes 
Association, the authors of a 3.3 million population-
based study proposed that patients with T2DM should be 
treated with antiplatelet drugs, statins, ACE inhibitors, 
or angiotensin receptor blockers, because they carry the 
same CV risk as patients with a history of MI (Schramm 
et al 2007).
Although CVD accounts for a high proportion of deaths, 
patient awareness remains low (CDC 2003), and opportuni-
ties to intervene and modify the risks are missed. The high 
risk of morbidity and mortality in patients with diabetes 
indicates that it is vital to implement timely interventions in 
order to minimize CV complications (Stolar et al 2003).
Factors contributing to increased 
CV risk in diabetes
Patients with T2DM usually present various factors contribut-
ing to the risk of CV problems. These include hyperglycemia 
and ﬂ  uctuation of blood glucose, central (visceral) obesity, 
hypertension, lipid abnormalities, hyperinsulinemia, and 
endothelial dysfunction (Stolar et al 2003).
The increased risk of CV morbidity and mortality associ-
ated with diabetes has led to the concept that hyperglyce-
mia may be one of the risk factors for CVD (Haffner et al 
2003). A prospective study of CVD in patients with T2DM 
reported that CVD episodes at 6.3 years were related to 
baseline HbA1c (Rius Riu et al 2003). A signiﬁ  cant increase 
in the risk for CV events and mortality has been reported in 
patients with HbA1c  7% compared with those who had 
lower HbA1c values (Kuusisto et al 1994). The UK Prospec-
tive Diabetes Study (UKPDS) showed a more than 2-fold 
increase in incidence of MI over a range of HbA1c values 
from  6% to  10%; each 1% reduction in HbA1c was 
associated with a reduction in risk of 21% for any diabetes 
endpoint and death, and 14% for MI (Stratton et al 2000) 
(Figure 1).
PPG control also plays a signiﬁ  cant role in overall glycemic 
control and becomes even more important than fasting plasma 
glucose (FPG) when better control (eg, HbA1c level  8.4%) 
is achieved (Monnier et al 2003). Excessive postprandial 
hyperglycemia may also be an important independent contribu-
tor to the risk of CV complications and mortality in T2DM 
(Massi-Benedetti and Federici 1999; Ceriello et al 2006). 
Interestingly, the deterioration of glucose homeostasis in the 
evolution of T2DM progresses from postprandial to fasting 
hyperglycemia (Monnier et al 2007). The Diabetes Interven-
tion Study showed that PPG level can be used to predict the 
risk of MI (Hanefeld et al 1996). In a more recent, 5-year 
prospective study, PPG was an independent CVD risk factor in 
patients with T2DM, particularly women (Cavalot et al 2006). Vascular Health and Risk Management 2008:4(3) 563
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Thus, attaining glycemic control, and reducing CVD risk, may 
be difﬁ  cult without adequate control of PPG levels.
Another major risk factor for developing T2DM is obesity. 
An estimated 80% of patients with T2DM are overweight and of 
that 37% are obese prior to diagnosis (Wolf and Colditz 1998). 
Epidemiological studies have demonstrated a clear association 
between obesity and CVD (Lemieux and Despres 1994), with 
visceral rather than peripheral fat being most harmful. A recent 
cross-sectional study of 44,042 patients with T2DM reported 
that 80% were overweight and 37% obese (Ridderstraale 
et al 2006). Such excessive weight is associated with insulin 
resistance, impaired glucose homeostasis, dyslipidemia, and 
hypertension – all risk factors associated with CVD.
Hypertension is also a major risk factor for such 
microvascular and macrovascular complications as reti-
nopathy, nephropathy, stroke, and MI. It is estimated that 
the prevalence of hypertension in T2DM ranges from 20% 
to 60% (ADA 2002), more than twice that seen in controls. 
In the Multiple Risk Factor Intervention Trial (MRFIT), 
mortality risk increased with increasing blood pressure, 
and the absolute level of risk in patients with diabetes was 
at least 3 times higher than that in controls (Stamler et al 
1993). In another study of patients with T2DM, hypertension 
and HbA1c at baseline were related to CVD episodes after 
6 years (Rius Riu et al 2003). The UKPDS demonstrated that 
blood pressure control achieved with lifestyle modiﬁ  cation 
and pharmacotherapy can result in risk reductions of 24% in 
diabetes-related endpoints, 32% in diabetes-related deaths, 
and 44% in stroke (UKPDS 38 1998).
Another complication associated with diabetes is a 
chronic, low-level inﬂ  ammatory state, possibly caused by 
oxidative stress or by glycosylation of proteins that activate 
macrophages. Elevated levels of C-reactive protein – a 
marker of subclinical inﬂ  ammation – present in patients 
with T2DM, especially among older age groups (Kalofoutis 
et al 2006), have been identiﬁ  ed as a predictor of ﬁ  rst MI 
and CVD (Ridker et al 2000). In case of impaired metabolic 
state, postprandial hyperglycemia increases the magnitude 
and duration of systemic inﬂ  ammatory responses, possibly 
promoting the development of T2DM and CVD (Kempf 
et al 2006). Elevated C-reactive protein levels have also 
been reported in patients with type 1 diabetes (T1DM) 
without macrovascular disease, suggesting that inﬂ  ammation 
precedes atherosclerosis (Schalkwijk et al 1999).
Lipid abnormalities such as elevated levels of triglyc-
erides (TG), small dense LDL cholesterol and decreased 
levels of HDL cholesterol have been consistently reported 
in diabetes, and these abnormalities dramatically increase 
the risk of macrovascular disease (Reaven 1995). In the 
Diabetes Control and Complications Trial (DCCT), treating 
T1DM subjects intensively for a mean of 6.5 years showed 
that high total cholesterol, high LDL cholesterol, high HbA1c 
at baseline were associated with the development of CVD 
during the 17 years of follow-up (Nathan et al 2005). In a 
7-year study of patients with T2DM, a previous history of 
MI, low HDL cholesterol, high LDL cholesterol, high TG, 
and high FPG was associated with a 2-fold increase in the 
risk of CVD morbidity and mortality (Lehto et al 1997). In 
T2DM, high postprandial TG responses have been associated 
with MI (Carstensen et al 2004).
Barriers to effective blood glucose 
management in diabetes
Before considering the treatment options for CVD risk in 
diabetes, it should be noted that there are several poten-
tial barriers to achieving good glycemic control. Lifestyle 
issues such as diet, exercise, and weight control are of great 
importance in managing T2DM, and represent vital oppor-
tunities for patients to inﬂ  uence their prognosis with regard 
to CV complications (O’Keefe et al 1999). Regular exercise, 
weight loss, and a special diet have been demonstrated to 
improve insulin sensitivity (Manson et al 1992; Wing et al 
1995; Knopp et al 1997), which may be beneﬁ  cial for the 
prognosis of T2DM, but many patients with T2DM have 
long-established behavioral patterns and ﬁ  nd it very hard to 
modify their dietary and exercise habits.
The risk of hypoglycemia always exists when blood glu-
cose-lowering therapies are used in patients with diabetes, 
and this is especially problematic with exogenous insulin 
therapy. The fear of hypoglycemic events can limit the glyce-
mic control that patients will strive for, and their CV risk may 
consequently remain higher than necessary (Davies 2004).
As noted above, many patients with T2DM are over-
weight. Diabetes treatments can cause further, unwelcome 
weight gain (Korytkowski 2002). Even when weight gain 
is not at a clinically signiﬁ  cant level, the mere prospect 
of gaining weight may jeopardize treatment adherence, 
preventing patients from achieving glycemic targets and 
indirectly increasing their risk of CVD.
Injection tolerability and the impact of therapy on 
lifestyle can also be barriers to diabetes treatment. Inject-
ing insulin often becomes a necessity in T2DM, but for 
some patients, multiple daily injections may be a source of 
anxiety, discomfort, or pain (Hanas and Ludvigsson 1997). 
Patients may consequently reduce their adherence to therapy, 
resulting in suboptimal glycemic control.Vascular Health and Risk Management 2008:4(3) 564
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Some non-modiﬁ  able risk factors may also play a role 
in CVD risk in diabetes. Female gender appears to increase 
CVD risk in diabetes; women treated with insulin have an 
especially high mortality risk (Kronmal et al 2006). Different 
ethnic groups may have different CV risk factors, such as 
body weight, lipid proﬁ  les, and blood pressure (Davis et al 
2001), and a genetic component demonstrated in twin studies 
may also inﬂ  uence CVD risk in T2DM (Medici et al 1999; 
Poulsen et al 1999). Finally, a higher cost of insulin analogs 
than that of human insulin may also represent a barrier for a 
number of patients. For others, the improved predictability, 
tolerability, and ﬂ  exibility of analogs may make the added 
expense more acceptable. Better adherence and fewer com-
plications may translate to cost beneﬁ  ts and fewer medical 
expenses in the long-term (Meece 2006). Although cost, 
treatment satisfaction and other issues may have an important 
role in the treatment of T2DM they will not be discussed in 
detail here since the scope of this review is restricted to the 
clinical aspects of combining insulin and OADs.
Glucose-lowering therapy 
and CV risk markers
The mechanisms by which improved glycemic control 
reduces CV risk are not completely understood, but probably 
relate to improvement of dyslipidemia, endothelial dysfunc-
tion, vasomotor dysfunction, and coagulation abnormalities, 
all of which are aggravated by hyperglycemia (Avena et al 
1998; Meigs et al 2000; Mather et al 2001). The recogni-
tion that achieving speciﬁ  c glycemic goals can substantially 
reduce morbidity has made the effective treatment of hyper-
glycemia a top priority in T2DM.
Initially, such lifestyle changes as diet, exercise and 
weight loss are utilized in order to reduce the insulin require-
ments of patients with diabetes. Since T2DM is a progres-
sive disease that causes deterioration over time, addition of 
medication is the rule, not the exception, if treatment goals 
are to be met (UKPDS 33 1998; Turner et al 1999; Nathan 
et al 2006). OADs can be taken as monotherapy or in com-
bination, and are designed either to increase insulin secretion 
or increase tissue sensitivity (Turner et al 1996). Metformin 
and thiazolidinediones (TZD) are often used as ﬁ  rst-line 
OADs in an attempt to utilize the insulin still available in 
patients’ circulation. These OADs can lower blood glucose 
with a low risk of hypoglycemia, but require the availability of 
endogenous insulin in order to exert a blood glucose-lowering 
effect. When OADs do not enable patients to reach glycemic 
targets, sulphonylureas (SUs) are often added. SUs increase 
pancreatic insulin secretion as long as sufﬁ  cient beta-cell 
function is preserved, but can precipitate hypoglycemia. 
Their efﬁ  cacy is comparable to that of the various OADs in 
improvement of glycemic control, with HbA1c reductions of 
1% to 2% usually achieved (Bailey 2003). With the excep-
tion of metformin, however, clear evidence is lacking for a 
reduction in macrovascular disease speciﬁ  cally associated 
with OADs (Macfarlane et al 2007).
With the number of oral treatment options currently avail-
able, it is important to consider the pathogenesis of T2DM 
and the risk factors for long-term CV consequences, vascular 
dysfunction, and inﬂ  ammation when selecting treatment. 
The conditions associated with diabetes mean that many 
patients are prescribed multiple medications, so it is also 
important to be aware of potential interactions, or at least of 
the comorbidities remaining to be investigated.
A recent systematic review (Bolen et al 2007) concluded 
that newer, more expensive agents such as TZD, Alpha-
glucosidase inhibitors, and meglitinides have effects on 
glycemic control and CV risk factors (blood pressure, lipids, 
and body weight) that are similar or superior to those of 
older agents such as SUs and metformin. An important issue 
neglected in this review is the additive effect on glycemic 
control obtained by combining different groups of OADs, 
since in order for patients to achieve effective improvement 
and reach their goals for glycemic control, a combination of 
OAD therapies is often used (Stolar et al 2003). For many 
patients, OAD therapy alone becomes inadequate over time, 
and insulin is added to the treatment regimen (Ahmed and 
Goldstein 2006). Indeed, at 9 years after diagnosis, almost 
80% of T2DM patients require insulin treatment (Turner et al 
1999; Wright et al 2002). Before reviewing the clinical stud-
ies using insulin plus OADs, the individual agents currently 
used in diabetes treatment will be brieﬂ  y discussed.
Metformin
Metformin suppresses hepatic glucose production and is 
thought to increase insulin sensitivity (Goldstein 2002). It 
has been used for decades, and has a long record of safety. 
Metformin is usually the ﬁ  rst OAD used in obese patients 
because – unlike other agents, such as SUs – it does not lead 
to weight gain (Hermann et al 1994). In combination therapy, 
metformin also appears to limit the weight gain associated 
with the use of other agents, such as TZDs and SUs (Turner 
et al 1998; Hermansen and Mortensen 2007). Metformin 
appears to reduce CV events, although the mechanism is 
not well understood.
A meta-analysis of 41 randomized controlled trials 
(RCTs) of metformin involving more than 3000 patients Vascular Health and Risk Management 2008:4(3) 565
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with T2DM reported that metformin effectively lowered 
HbA1c and modestly reduced total and LDL cholesterol, 
but had no signiﬁ  cant effect on blood pressure, HDL choles-
terol, or triglycerides (Wulffelle et al 2004). Indeed, in the 
ADOPT study, glyburide was associated with a lower risk 
of cardiovascular events than metformin and rosiglitazone 
(Kahn et al 2006) However, the majority of studies have 
reported beneﬁ  cial CV effects with metformin. The UKPDS 
showed that the intensive use of metformin in obese patients 
achieved a reduction of 36% in all-cause mortality and 39% 
in MI (Turner et al 1998). Weight stabilization, improved 
lipid proﬁ  le, reduced triglycerides and LDL cholesterol, and 
increased HDL cholesterol (Buse et al 2004) have also been 
reported. Metformin has been shown to improve endothelial 
dysfunction – a factor closely linked to the development of 
atherosclerosis (Mather et al 2001). The Hyperinsulinemia 
the Outcome of its Metabolic Effects (HOME) double-blind 
trial, which assessed the metabolic and cardiovascular effects 
of metformin when added to insulin, reported a signiﬁ  cant 
improvement of endothelial function largely unrelated to 
changes in glycemic control (De Jager et al 2005). For these 
reasons, metformin has been the most commonly used drug 
in combination with insulin.
There are few limitations for the use of metformin, the 
most common of which include intolerance to its gastrointes-
tinal side effects and its contraindication in renal or hepatic 
insufﬁ  ciency (Ahmed and Goldstein 2006).
Thiazolidinediones
Insulin sensitizers, TZDs have become very popular in recent 
years because they exhibit more potent effects on metabolic 
syndrome parameters associated with insulin resistance 
than other OADs (Goldstein 2002). Although the precise 
mechanism of action of TZDs is still under investigation, it 
appears to be mediated by effects in adipose tissue. TZDs 
have been shown to cause redistribution of fat with a reduc-
tion in visceral adiposity, a marker of insulin resistance 
(Kelly et al 1999).
The TZDs pioglitazone and rosiglitazone have shown 
similar effects on glycemic control in T2DM, but differential 
effects on dyslipidemia. A recent meta-analysis of random-
ized, controlled trials showed differing outcomes on lipid 
proﬁ  les (Chiquette et al 2004). Pioglitazone had a neutral or 
beneﬁ  cial effect on lipids, whereas rosiglitazone appeared to 
have more complex effects, including an associated increase 
in both LDL and total cholesterol and a neutral effect on 
TGs. Both drugs increased levels of HDL cholesterol. 
Improvements in endothelial dysfunction with associated 
reduction in microalbuminuria have also been reported 
(Watanabe et al 2000) independently of reduction in glycemia 
and blood pressure (Bakris et al 2003). The effects of TZDs 
on blood pressure have not been consistent, but reduction of 
blood pressure has been reported (St. John Sutton et al 2002). 
TZDs also appear to decrease plasma C-reactive protein 
levels in patients with T2DM (Haffner et al 2002).
PROACTIVE, a large study in more than 5000 patients 
with T2DM and known CVD, assessed the effect of pio-
glitazone on CV mortality and morbidity (Dormandy et al 
2005). In this high-risk study population, an aggressive dose 
titration of pioglitazone or placebo was used as ‘add-on’ 
therapy to current treatment regimes to ensure the best pos-
sible glycemic control. There was a nonsigniﬁ  cant reduction 
in the primary composite endpoint after a mean follow-up 
of 34 months, and an HbA1c reduction of 0.5% (HR 0.90; 
p = 0.095); however, despite a signiﬁ  cant reduction in the 
secondary composite endpoint of all-cause mortality, non-
fatal MI and stroke were observed (HR 0.84; p = 0.027) 
(Dormandy et al 2005).
There are also side effects associated with TZD use, 
including fluid retention (which can lead to significant 
weight gain), dilutional anemia and ﬂ  uid overload. TZDs 
are contraindicated in patients with heart failure (Higgs and 
Krentz 2004). Importantly, the use of TZDs with insulin 
has been associated with an increased risk of heart failure 
(Kermani and Garg 2003). TZDs are consequently contra-
indicated with insulin use in some countries. In addition, a 
recent meta-analysis of 42 trials showed that rosiglitazone 
slightly increased the risk of MI, and might also increase the 
risk of CV death (Nissen and Wolski 2007). This ﬁ  nding has 
instigated a heated discussion among opinion leaders, but no 
deﬁ  nitive conclusions on safety have been reached to date.
Insulin secretagogues
SUs were a ﬁ  rst-line treatment before the introduction of met-
formin and TZDs; currently, however, they are often placed 
second after metformin, and sometimes even third after TZDs 
(Ahmed and Goldstein 2006). Unlike metformin, SUs have 
not shown any consistent protective role in the development 
of CVD; moreover, it has been proposed that patients treated 
with SUs are at an increased risk of macrovascular disease. 
For example, the UKPDS reported mixed results associated 
with the use of SUs. Although there was a trend towards a 
16% reduction in fatal and non-fatal myocardial infarction 
(Stratton et al 2000), increased mortality was reported in 
patients treated with SUs plus metformin (Turner et al 1998); 
however, SU-treated patients were an average of 5 years older, Vascular Health and Risk Management 2008:4(3) 566
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were more hyperglycemic, and were followed for 5 years less 
than patients who were not treated with SUs.
The main side effects associated with the use of SUs 
include weight gain (up to several kg) and hypoglycemia, 
the latter occurring more frequently with the longer-acting 
SUs (eg, glibenclamide, glyburide). SUs have not been 
shown to improve blood pressure, and do not appear to have 
a consistent effect on lipids (Bailey 2003).
Alpha-glucosidase inhibitors
Alpha-glucosidase inhibitors (AGIs) reduce the rate 
of digestion of polysaccharides in the proximal small 
intestine, primarily lowering postprandial glucose levels 
without causing hypoglycemia. They are less effective 
than metformin or SUs, reducing HbA1c by 0.5% to 0.8% 
(Van de Laar et al 2005). Gastrointestinal side effects are 
common with AGI treatment, and have led to discontinu-
ation in 25% to 45% of participants in clinical trials (Van 
de Laar et al 2005). Interestingly, a recent meta-analysis 
of 7 long-term studies of AGI treatment with acarbose in 
T2DM demonstrated a reduction in CV events (Hanefeld 
et al 2004); however, this meta-analysis has been criticized 
for a number of reasons such as publication bias, heteroge-
neity, detection bias, and confounding factors (Van de Laar 
and Lucassen 2004). A recent Cochrane systematic review 
and meta-analysis of 41 studies of AGI monotherapy in 
patients with T2DM of at least 12 weeks did not detect 
any effect on CV morbidity or mortality (Van de Laar et al 
2005). A potential beneﬁ  t of AGI on CVD therefore still 
needs to be proven.
Insulin
It has been shown that hyperglycemia contributes to an 
increased risk of microvascular complications (nephropathy, 
retinopathy, and neuropathy) (Harris 1998), and that lowering 
glucose levels protects against these complications (DCCT 
1993; Turner et al 1998; UKPDS 33 1998). Controlling 
blood glucose with insulin has the potential to be the most 
effective blood glucose-lowering therapy. Insulin is consis-
tently reported to reduce microvascular complications such 
as small vessel arterial disease, retinopathy, nephropathy, 
and neuropathy (DCCT 1993; UKPDS 33 1998). In the 
UKPDS, intensive blood glucose control resulted in a 16% 
reduction in the risk of MI and a 25% reduction in the risk 
of microvascular complications (Turner at al 1998); however, 
there have been conﬂ  icting views in the past as to whether 
insulin actually beneﬁ  ts CVD risk. Some observational 
studies have reported an association between high insulin 
levels and an increased risk of CVD (Janka at al 1987; Liu 
et al 1992), and it has been suggested that hyperinsulinemia 
predisposes patients to atherosclerosis and its complications 
(O’Keefe et al 1999).
The RCTs comparing intensive and conventional insu-
lin treatment have more often focused on microvascular 
rather than macrovascular complications (Muis et al 2005). 
An exception was the Diabetes Mellitus Insulin Glucose 
Infusion in Acute Myocardial Infarction (DIGAMI) study, 
which assessed the impact of insulin infusion (followed by 
subcutaneous insulin injections) in patients with T2DM and 
acute MI (Malmberg et al 1995, 1997). Here, a reduction 
of 28% (p   0.05) in relative mortality was reported after 
3.4 years in the insulin infusion group compared with a 
conventional treatment group (Malmberg et al 1995, 1997). 
However, DIGAMI 2 did not support this ﬁ  nding, or the idea 
that insulin-based treatment lowers the number of nonfatal 
myocardial reinfarctions and strokes (Malmberg et al 2005). 
This disappointing outcome may in part be due to difﬁ  cul-
ties experienced with recruitment and reaching targets, and 
the subsequent premature recruitment stop in DIGAMI 2 
(Malmberg et al 2005).
Although some studies report that insulin-treated patients 
with diabetes have a worse CV prognosis than patients not 
treated with insulin (Mak et al 1997), this may be seen as 
intrinsic to the disease process. Patients with more severe 
diabetes are more likely to be treated with insulin (O’Keefe 
et al 1999), and insulin users may have had chronically raised 
blood glucose in the past (in the ‘pre-diabetic range’), with 
CVD symptoms emerging years later – perhaps around the 
same time as the need for insulin treatment arose. Atheroscle-
rosis progresses over many years, and the process is likely 
to begin long before treatment intervention. Insulin users, 
therefore, are by deﬁ  nition likely to have accrued vascular 
damage by the time they initiate insulin treatment.
As noted above, most RCTs have not directly investigated 
the association between insulin use and risk of CV events. 
However, a number of studies suggest that reduced blood 
glucose achieved through intensive insulin treatment will 
ultimately have a beneﬁ  cial effect on CV risk. For example, in 
the Diabetes Control and Complications Trial/Epidemiology 
of Diabetes Intervention and Complications (DCCT/EDIC) 
study in T1DM, it was shown that intensive treatment has 
long-term beneﬁ  cial effects on the risk of CVD (Nathan et al 
2005). During 17 years of follow-up, intensive treatment 
reduced the risk of any CVD events by 42%, and the risk of 
nonfatal MI, stroke, or death from CVD by 57% (Nathan et al 
2005). The intensive therapy during the DCCT/EDIC study Vascular Health and Risk Management 2008:4(3) 567
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resulted in decreased progression of intima-media thickness 
6 years after the end of the trial (Nathan et al 2003). The 
long-term follow-up data suggest that previous intensive 
treatment of T1DM has an extended beneﬁ  t well beyond the 
treatment period.
In the Steno study (Gaede et al 1999), T2DM patients with 
microalbuminuria were treated for a variety of CVD risk fac-
tors with multiple interventions, including insulin. Intensiﬁ  ed 
intervention reduced the risk for a combined endpoint of CV 
mortality, nonfatal MI, nonfatal stroke, coronary intervention, 
revascularization to legs, and amputation by 50% (Gaede 
and Pedersen 2004). This study clearly showed that when an 
integrated cardiovascular risk factor management program 
is employed that includes conventional cardiovascular drugs 
as well as insulin, a positive effect on CV prognosis is likely 
to be achieved in patients with T2DM.
Insulin with OADs and the
treat-to-target concept
The UKPDS was one of the ﬁ  rst studies to prospectively 
investigate outcomes in insulin-plus-OAD-treated patients 
with T2DM, and it showed that the risk of complications 
can be considerably reduced when ‘near-normal’ glycemic 
control is achieved (Davidson 2005; UKPDS 33 1998). It 
demonstrated that early addition of insulin to oral therapy 
can safely keep HbA1c close to 7.0% in the ﬁ  rst 6 years after 
diagnosis (47% of patients in the SU with insulin group vs. 
35% in insulin only group). (Wright et al 2002); however, 
the UKPDS did not use the modern insulin products cur-
rently available.
Many patients remain poorly controlled with OADs, 
and insulin initiation is often delayed and insulin doses not 
adjusted aggressively enough. When OAD therapy becomes 
insufﬁ  cient, there are several options for insulin initiation. 
Exogenous insulin administration often aims to mimic the 
physiological proﬁ  le of endogenous insulin secretion as 
closely as possible to match insulin supply to physiological 
need, but traditional human insulin products do not match 
this proﬁ  le precisely. Several types of insulin analogs have 
been developed by improving the pharmacokinetic proﬁ  le 
of human insulin that follows subcutaneous absorption, in 
order to achieve a better balance between glycemic control 
and tolerability of treatment. Long-acting insulin analogs 
simulate the low level, basal insulin secretion seen overnight 
and between meals, whereas rapid-acting insulin analogs have 
a fast onset and short duration of action designed to mimic the 
normal endogenous prandial insulin response, thereby limit-
ing mealtime glucose excursions. Premixed insulin analogs 
consist of a mixture of a rapid-acting insulin analog and a 
slower-acting protaminated form of the analog, providing 
both basal and prandial insulin in one injection.
In recent years, several studies have examined combi-
nation treatments with insulin analogs plus OADs using a 
treat-to-target (TTT) algorithm. Patients usually continued 
using OADs, while insulin analog was introduced and sys-
tematically titrated to a deﬁ  ned glucose target. These studies 
have shown that with aggressive insulin titration, HbA1c can 
be reduced to a clinically highly beneﬁ  cial level. A study by 
Riddle et al (2003) was the ﬁ  rst trial to use a TTT algorithm 
in patients poorly controlled with OADs, to which the basal 
analog insulin glargine was added. Dosage was titrated 
weekly towards a target FPG   5.6 mmol/L, and in 6 months, 
patients achieved impressive reductions in HbA1c, with the 
majority (~60%) reaching the target of HbA1c   7.0%.
Table 1 shows the results of trials comparing long-acting 
insulin analogs with NPH insulin in insulin-naïve patients 
with T2DM. Reductions in HbA1c are usually similar between 
regimens (up to 1.8%), with large proportions of patients 
achieving targets of HbA1c   7%. The lack of difference in 
glycemic control is unsurprising, of course, because of the 
use of a common glycemic target and titration algorithm; 
however, use of insulin analogs generally results in a signiﬁ  -
cantly lower risk of hypoglycemia than use of NPH. When 
basal insulin analogs are initiated, they can achieve clinically 
meaningful reductions in blood glucose together with a low 
risk of hypoglycemia (Figure 2). Thus, a key barrier to insulin 
titration is lowered, implying that in the everyday clinical 
setting, patients are more likely to be able to reach guideline 
glycemic targets without being thwarted by hypoglycemia.
Furthermore, when insulin detemir has been used, patients 
have achieved signiﬁ  cant improvements in glycemic control 
without the excessive weight gain usually associated with 
insulin use. Two recent studies of insulin detemir added to 
oral therapy showed HbA1c to decrease by 1.5% to 1.8%, 
with mean weight gain only half that seen with NPH insulin 
(Table 1) (Hermansen et al 2006; Philis-Tsimikas et al 2006). 
When patients use self-adjusted dosing algorithm, the HbA1c 
improvements are comparable to those of a physician-driven 
algorithm, and weight change can be minimal (0.1 kg) 
(Meneghini et al 2007). This weight advantage of detemir 
further appears to relate to body mass index (BMI): patients 
gain less weight with increasing BMI (Hermansen et al 
2006). These results suggest that with some insulin analogs, 
it is possible to achieve a good glycemic control with less 
weight gain than that of comparator insulins. It remains 
to be established whether better weight control is directly Vascular Health and Risk Management 2008:4(3) 568
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beneﬁ  cial to CVD risk; however, it may have a beneﬁ  cial 
effect on treatment compliance.
Patients who require insulin can also be started on a 
premixed insulin analog, which allows easy intensiﬁ  cation 
with additional injections of the same insulin. HbA1c reduc-
tions can be of a greater magnitude with premixed insulin 
analogs than with basal analogs (Table 2), largely because 
PPG can be better controlled with premixed human insulins 
than with basal insulin alone. For example, in a 6-month 
TTT study of insulin initiation, HbA1c was signiﬁ  cantly 
better and a greater proportion of patients reached the target 
HbA1c   7.0% with premixed insulin aspart than with the 
basal analog insulin glargine (66% vs. 40%, respectively) 
(Raskin et al 2005). A study by Garber et al (2006) employed 
an aggressive titration algorithm to reach the target FPG of 
4.5–6.1 mmol/L with premixed insulin aspart. The HbA1c 
target of  7.0% was achieved by 41% of patients with once-
daily, by 70% with twice-daily, and by 77% of patients with 
three times-daily premixed insulin aspart. Figure 3 shows that 
premixed insulins can achieve greater reductions in HbA1c 
than basal insulins, but with a slightly higher risk of hypo-
glycemia. Premixed insulin analogs may therefore represent 
an effective treatment option in terms of achieving glycemic 
control, although weight gain and the risk of hypoglycemia 
may be more of an issue than when basal insulin alone is 
added to OADs. A recently published study by the 4-T Study 
Group (Holman et al 2007) compared the use of premixed 
insulin aspart twice-daily, prandial insulin aspart three-times 
daily, and basal insulin detemir once daily (twice if required) 
in patients with type 2 diabetes inadequately controlled with 
metformin and SUs. After 1 year, HbA1c levels were similar 
in the premixed insulin group (7.3%) and the pradial group 
(7.2%), but higher in the basal group (7.6%). However, the 
respective mean numbers of hypoglycemic events per patient 
per year were 5.7, 12.0, and 2.3, and weight gains were 4.7 kg, 
5.7 kg, and 1.9 kg, suggesting that premixed insulin aspart 
and prandial insulin aspart reduced HbA1c levels more than 
basal insulin detemir but were associated with greater risks 
of hypoglycemia and weight gain (Holman et al 2007).
There is currently no consensus as to which option repre-
sents the best way to initiate and intensify insulin treatment. 
Patients are often started on a once-daily basal insulin ana-
log at bedtime, which improves FPG with a relatively low 
risk of nocturnal hypoglycemia. Using this strategy, PPG 
excursions may be controlled by a combination of OADs 
and the recovered beta-cell secretory capacity that basal 
insulin supplementation may afford. There does seem to be 
a limit to the HbA1c reduction that can be achieved when 
Table 1 Trials of basal insulin analogues in insulin-naïve patients with type 2 diabetes
Author HbA1c FPG Hypoglycemia Weight gain (kg) Dose
Baseline End Baseline End
Hermansen 2006 Detemir NPH 8.6 6.8 11.1 6.9 RR 0.53a 1.2a BD
8.5 6.6 10.8 6.6 2.8 ttt
Philis-Tsimikas 2006 Detemir am or pm 
NPH
9.1 7.5 11.5 8.6 RR 0.68 1.2 OD
8.9 7.4 10.8 7.2 RR 0.47a 0.7b ttt
9.2 7.4 11.5 7.8 1.6
Yki-Jarvinen 2000 Glargine NPH 9.1 8.34 ∼34%c 2.57 OD
8.9 8.24 ∼42% 2.34
Massi-Benedetti 2003 Glargine NPH 9.0 8.5 13.0 9.6 35% 2.01 OD
8.9 8.5 13.1 9.8 41% 1.88
Fritsche 2003 Glargine am or pm 
NPH
9.1 7.8a 12.1 7.0 74% 3.9 OD
9.1 8.1b 12.0 6.8 68% 3.7
9.1 8.3 12.2 6.9 75% 2.9
Riddle 2003 Glargine NPH 8.61 6.96 11.0 6.5 13.9c 3.0 OD
8.56 6.97 10.8 6.7 17.7 e/pt/yr 2.8 ttt
Eliaschewitz 2006 Glargine NPH 9.03 7.65 11.2 6.4 52.8%c Not reported OD
9.21 7.78 10.8 6.6 62.8% ttt
Notes: Between-treatment comparison: ap   0.001; bp   0.01; cp   0.05.
Abbreviations: ttt, treat-to-target study; hypoglycemia RR, relative risk; %, % of patients experiencing hypos; e/pt/y, events per patient year.Vascular Health and Risk Management 2008:4(3) 569
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basal insulin alone is added to OADs, as evidenced by the 
observation that studies involving cohorts with higher base-
line levels of HbA1c tend to achieve mean absolute HbA1c 
levels at endpoint that, while improved, remain above target 
(De Vries et al 2007). There is also evidence that the effect 
of a once-daily basal insulin is more likely to wane across 
24 hours when baseline control is poorer, and that splitting 
the dose will merely escalate the dose without a correspond-
ing gain in control (DeVries et al 2007). These observations 
likely reﬂ  ect in part an increasing failure to limit postprandial 
glycemic control with progressing T2DM.
Furthermore, as HbA1c decreases, so PPG contributes 
an increasing proportion of the residual hyperglycemia 
(Monnier et al 2003). It follows that in order to achieve 
HbA1c treatment goals, PPG control must be targeted as well, 
particularly in more advanced disease. When OADs no longer 
adequately control PPG excursions, prandial insulin can be 
added at mealtimes, one meal at a time, to a simple basal 
insulin regimen. Alternatively, premixed insulin formulations 
can be used for insulin initiation and intensiﬁ  cation of treat-
ment, with the advantage of fewer daily injections but more 
limited ﬂ  exibility. Using this approach, patients can use the 
same insulin in the same device, just increasing the number 
of daily injections (Garber et al 2006). Ongoing studies will 
likely discern patient preferences and the optimal treatment 
strategies for deﬁ  ned patient types.
Conclusions
It is well established that patients with diabetes are at a 
high risk of CVD. Blood glucose control appears to be an 
important factor in reducing the CVD risk and potential CV 
mortality in diabetes patients. Most studies examining insu-
lin plus OADs have focused on insulin, with OADs usually 
grouped together – although most trials have used metformin 
as either the only OAD or in combination with other OADs 
(eg, Riddle et al 2003; Hermansen et al 2006; Philis-Tsimikas 
et al 2006). The combination of insulin plus OADs has been 
associated with improvements in CV risk markers in early 
outcome studies, but studies examining the interactions of 
various antidiabetic treatments would also be helpful.
The TTT studies have shown that insulin analogs plus 
OAD can help patients to achieve excellent glycemic control. 
Adding a basal insulin analog to OAD therapy improves 
HbA1c by 1.5% to 1.8%, with a low risk of hypoglycemic 
events. Premixed insulin analogs have shown greater HbA1c 
reductions, but considerable weight gain; however, the long-
acting insulin analog detemir appears to limit the weight 
gain usually present with insulin use (Hermansen et al 2006; 
Philis-Tsimikas et al 2006). This effect may help improve 
adherence to treatment.
There are different views as to which approach is the 
best option for initiation or intensiﬁ  cation of insulin, when 
the need arises. With a basal insulin analog injection as a 
start, rapid-acting insulin can be added at mealtimes. On the 
other hand, premixed insulin analogs contain both basal and 
prandial insulin in one injection. The clinician and patient 
must decide which of these options they ﬁ  nd more acceptable. 
Observational studies have also shown that patients can easily 
manage self-monitoring and self-titration of insulin analogs 
(Davies et al 2005; Meneghini et al 2007). Insulin analogs 
appear to be a better option than conventional insulins for 
achieving the balance between glycemic control and risk 
of hypoglycemia. Data concerning the impact of different 
Figure 2 Mean change in HbA1c (baseline to endpoint) and relative risk for all-day hypo-
glycemia in comparative trials of basal analogs vs. NPH insulin plus OADs in T2DM.
Note: deﬁ  nitions of hypoglycemia vary by study; the glargine ‘relative percentages’ 
have been derived from the study publications and are not comparable to the relative 
risk data presented for detemir. ap   0.05 for between treatment difference in change 
in HbA1c between baseline and end of trial, or in risk of hypoglycaemia (De Vries 
et al 2007 [in press]). © Reproduced with permission.Vascular Health and Risk Management 2008:4(3) 570
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insulin plus OAD regimens on CVD markers other than 
hyperglycemia are currently lacking, yet have the potential 
to guide treatment choices.
The role of OAD and of insulin-OAD combination regi-
mens may change in the future as a result of the development 
of newer therapies. For example, glucagon-like peptide 1 
(GLP-1) analogs, GLP-1 agonists and dipeptidyl peptidase 
IV (DPP-4) inhibitors represent very promising treatment 
options for patients with T2DM. GLP-1 secretion may be 
impaired in T2DM, and GLP-1 analogs and agonists and 
DPP-4 inhibitors that increase endogenous GLP-1 produc-
tion have the advantage that their effect on insulin secretion 
depends on plasma glucose concentration. The ﬁ  rst studies of 
GLP-1 analogs show encouraging improvements in glycemic 
control without the risk of hypoglycemia and with a dose-
dependent reduction in weight, a combination promising a 
potential CVD beneﬁ  t (DeFronzo et al 2005; Vilsbøll et al 
2006). It should be noted that despite its HbA1c- lowering 
effect, the DPP-4 inhibitor sitagliptin increases the risk of 
hypoglycemia when combined with SUs (Hermansen et al 
2007). Although it remains to be determined whether these 
agents are likely to be used with insulin, an agent controlling 
glucose levels while decreasing weight gives rise to hope for 
beneﬁ  cial treatment possibilities. Large, long-term compara-
tive studies of major clinical endpoints, such as CVD, MI, 
and CV mortality, are needed to determine the comparative 
effects of OADs
In summary, it seems sensible to establish glycemic control 
in patients with T2DM by utilizing such lifestyle changes as diet 
intervention and exercise; however, current studies have shown 
that excellent glycemic control will ultimately require insulin 
treatment, at least in the more advanced stages of T2DM, and 
that this can be achieved with insulin plus OAD with a TTT 
approach. Patients and clinicians need to gain more conﬁ  dence 
Table 2 Trials of premixed insulin analogues in patients with type 2 diabetes
Author HbA1c FPG Hypoglycemia Weight gain Dose
Baseline End Baseline End
Insulin-naïve patients
Malone 2004 Mix25 8.7 7.4b 8.5 7.7c 0.68c mi  2.3b BID
Glargine 8.7 7.8 8.5 6.9 0.39 e/pt/30 days 1.6 OD
Kilo 2003 BIAsp 30 9.5 8.2e 13.4 9.2e 43% 0.7 OD
BHI 9.3 8.2e 12.6 9.1e 32% 1.0 OD
Raskin 2005 BIAsp 30 9.7 6.9b 14.0 7.1 3.4c 5.4b BID
Glargine 9.8 7.4 13.5 6.5 0.7 e/pt/yr 3.5 OD ttt
Kann 2006 BIAsp 30 9.21 7.5a 11.0 8.6 20.3%c 0.7 BID
Glargine 8.9 7.9 11.5 9.1 9% mi 1.5 OD
Patients previously treated with insulin
Roach 1999 Mix 25 7.8 42% BID
BHI 30 8.1 35% BID
Roach 1999 Mix 25 7.7 8.9 40% none BID
BHI 30 7.7 9.0 37% BID
Malone 2005 Mix 25 8.5 7.5a 8.4 7.9b 0.61 0.8a BID
Glargine 8.5 8.1 8.4 7.4 0.44 e/pt/30 days 0.1 OD
Boehm 2002d BIAsp 30 8.4/8.1 8.1 8.9 20mj/362mi BID
BHI 30 8.4/8.2 8.2 8.2 42mj/361mi BID
Liebl 2006 BIAsp 30 8.4 7.2b 11 8.1 28% 2.2 BID
Detemir +
aspart
8.2 7.0 11.2 8.2 31% mi 2.2 OD
Garber 2006 BIAsp 30 8.6 7.2 9.2 6.4 15.4 ∼0.5 OD,
22.4 BID,
12.0 e/pt/yr TID ttt
Notes: Between-treatment comparison: ap   0.001; bp   0.01; cp   0.05; dIncludes type 1 and 2 diabetes patients; eCalculated value.
Abbreviations: ttt, treat-to-target study; hypoglycemia %, % of patients experiencing hypos; e/pt/y, events per patient year; mj, major; mi, minor.Vascular Health and Risk Management 2008:4(3) 571
Insulins with oral antidiabetic agents and cardiovascular risk
in initiating and titrating insulin, as this approach can lead to a 
better prognosis in terms of diabetes complications, including a 
reduced risk of CVD. A comprehensive approach for preventing 
and/or ameliorating the CV complications of diabetes would 
also require the use of lipid-lowering medication, control of 
blood pressure, and anticoagulation medication.
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